Leadership

Adam Simpson

Adam Simpson

Chief Executive Officer

Adam Simpson is the chief executive officer (CEO) of Icosavax. He has substantial life science operational and emerging company experience and has executed significant partnering and acquisition transactions. Previously, Adam was CEO of PvP Biologics, another spinout from University of Washington’s Institute for Protein Design (IPD), from company creation through its sale to Takeda. Prior to joining PvP Biologics, he was the president and chief operating officer of Cypher Genomics, a genome interpretation company focused on biomarker discovery to facilitate

Douglas Holtzman, Ph.D., M.P.H.

Douglas Holtzman, Ph.D., M.P.H.

Chief Scientific Officer

Douglas Holtzman, Ph.D., M.P.H. is the Chief Scientific Officer (CSO) of Icosavax. He has more than 25 years of experience in industry and the philanthropic sector leading and funding innovative research and development activities with an emphasis on vaccines. Prior to Icosavax, he was Vice President, Discovery at Takeda Pharmaceuticals, where he led a team working on dengue and norovirus vaccine candidates. He was also a member of the management committee that helped to globalize Takeda’s Japan-based vaccines business. Prior

Niranjan Kanesa-thasan, M.D., MTMH, FIDSA, FASTMH

Niranjan Kanesa-thasan, M.D., MTMH, FIDSA, FASTMH

Chief Medical Officer

Niranjan Kanesa-thasan, M.D., MTMH, FIDSA, FASTMH is the Chief Medical Officer (CMO) of Icosavax and is a global medical executive with a successful 25-year career in vaccine research and development leading to seven licensed vaccines. He has extensive leadership and management experience in the biopharmaceutical industry (vice president, GSK Vaccines and Novartis Vaccines; Acambis, acquired by Sanofi Pasteur), government (Walter Reed Army Institute for Research, US Army Medical Research Institute for Infectious Diseases), and academia (Uniformed Services University of the

Thomas Russo

Thomas Russo

Chief Financial Officer

Thomas Russo is the Chief Financial Officer (CFO) of Icosavax. He has more than 25 years of diverse industry experience, including in finance and operations for public biopharma companies, as well as in the investment community. Prior to Icosavax, Tom was CFO of Assembly Biosciences, where he contributed to more than $220 million of gross proceeds raised through the capital markets and non-dilutive sources of financing. Previously, he held roles across finance and commercial operations Gilead Sciences, Inc., including serving

Cassia Cearley, Ph.D.

Cassia Cearley, Ph.D.

Chief Business Officer

Cassia Cearley, Ph.D. is the Chief Business Officer (CBO) of Icosavax. Cassia has worked with pharmaceutical companies in various roles for more than 10 years. Prior to joining Icosavax, Cassia was the vice president of research for Aptinyx Inc., where she led a team responsible for building a portfolio of small molecule NMDA receptor modulators. Prior to this, Cassia was on the corporate development team of Naurex Inc, which was responsible for the spinout of Aptinyx Inc. and the sale

Elizabeth Bekiroğlu

Elizabeth Bekiroğlu

General Counsel

Elizabeth Bekiroğlu is the General Counsel of Icosavax. She brings more than 15 years of experience advising pharmaceutical and biotechnology companies on a broad range of legal matters. Prior to joining Icosavax, Ms. Bekiroğlu was Associate General Counsel at Seagen, where she helped lead and build the legal affairs group as Seagen transformed into a global, multi-product company. Previously, she led the legal function at Oncothyreon, where she handled a wide range of corporate, securities, clinical, manufacturing, licensing, and transactional

Charles Richardson, Ph.D.

Charles Richardson, Ph.D.

Senior Vice President, Technical Operations

Charles (Chuck) Richardson, Ph.D. is the senior vice president (SVP), Technical Operations of Icosavax, with responsibility for CMC development and manufacturing for Icosavax vaccines. Chuck has more than 30 years of experience in biopharmaceutical development with demonstrated leadership capability in a global environment. His experience includes planning, implementing, and managing research and product development, as well as manufacturing and engineering and quality systems. Prior to joining Icosavax, he was vice president, head of Global CMC for Takeda Vaccines, with responsibility

Ami Shah Brown, Ph.D., MPH

Ami Shah Brown, Ph.D., MPH

Senior Vice President, Regulatory Affairs

Ami Shah Brown, Ph.D., MPH, is the Senior Vice President, Regulatory Affairs of Icosavax. She has more than 20 years of experience in vaccine development for infectious diseases. Prior to joining Icosavax, Ami was Senior Vice President, Regulatory Affairs for Inovio Pharmaceuticals. During her 10-year tenure, she was the global regulatory liaison for biologics, medical devices, and combination products spanning all phases of clinical trials through to licensure. She has also held positions at the John Hopkins Center for Immunization

Lori Stewart

Lori Stewart

Vice President, People and Culture

Lori Stewart is the Vice President, People and Culture of Icosavax. She has more than 25 years of experience in human resources leading people strategy, professional growth programs, recruiting, diversity and inclusion, and organizational development. Prior to Icosavax, Lori was Vice President, People at Adaptive Biotechnologies, where she led early growth, learning and development, and talent management. Previously, Lori held human resources leadership roles in high growth companies across biotechnology, financial services, and technology industries. Lori holds an MBA from

Board of Directors

Terry Gould

Director

Peter Kolchinsky, Ph.D.

Director

Heidi Kunz

Director

Mark McDade

Chair

John W. Shiver, Ph.D.

Director

Adam Simpson

Chief Executive Officer

Ann Veneman

Director

Scientific Advisory Board
and Key Advisors

Neil King, Ph.D.

Chair, Scientific Advisory Board

Ralf Clemens, M.D.

Development Advisor and SAB Member

Jean-Paul Prieels, Ph.D.

SAB Member

David Baker Ph.D.

Co-founder

Christian Mandl, M.D., Ph.D.

SAB Member

Barney S. Graham, M.D., Ph.D.

SAB Member

Robin Robinson, Ph.D.

SAB Member